3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
6
Leukemia, Myeloid, Acute
4
Uveal Melanoma
2
Lymphoma
2
Leukemia
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Meningeal Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Kidney Diseases
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Interleukin-2
×
90 days
×
Clear all
No trials found.